JonesResearch initiated coverage of Evaxion Biotech (EVAX) with a Buy rating and $10 price target The firm says Evaxion is a clinical-stage company leveraging its AIdriven platform to develop vaccines. The company’s Phase 2 data in melanoma showed a durable clinical benefit and sustained immune response at the two-year cutoff, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Appoints Dr. Helen Tayton-Martin as CEO Amid Strategic Growth
- Evaxion Biotech appoints Tayton-Martin as new CEO
- Evaxion Biotech price target raised to $11 from $6 at Lake Street
- Buy Recommendation for Evaxion Biotech Amid Promising Phase 2 Study Results and Future Potential
- Evaxion Biotech trading resumes